Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation

Bone Marrow Transplantation

Volumn 51, Issue 7, 2016, Pages 999-1001

  Varma, A ^a,b   Saliba, R M ^b   Torres, H A ^b   Afrough, A ^b   Hosing, C ^b   Khouri, I F ^b   Nieto, Y ^b   Shah, N D ^b   Parmar, S ^b   Bashir, Q ^b   Ahmed, S ^b   Jones, R B ^b   Kebriaei, P ^b   Olson, A L ^b   Shpall, E J ^b   Alousi, A M ^b   Qazilbash, M H ^b   Champlin, R E ^b   Popat, U ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; AUTOLOGOUS STEM CELL TRANSPLANTATION; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HEPATITIS C; HODGKIN DISEASE; HUMAN; HYPERTRANSAMINASEMIA; LETTER; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; VIRUS LOAD; AGED; AUTOTRANSPLANTATION; BLOOD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPACIVIRUS; LYMPHOMA; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; VIROLOGY;

AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPACIVIRUS; HEPATITIS C; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84960154419     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2016.28     Document Type: Letter

References (15)

1. Kang J, Cho JH, Suh CW, Lee DH, Oh HB, Sohn YH, et al. High prevalence of hepatitis B and hepatitis C virus infections in Korean patients with hematopoietic malignancies. Ann Hematol 2011; 90: 159-164
2. Ferri C, Caracciolo F, Zignego AL, La Civita L, Monti M, Longombardo G, et al. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol 1994; 88: 392-394
3. Locasciulli A, Testa M, Valsecchi MG, Bacigalupo A, Solinas S, Tomas JF, et al. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation 1999; 68: 1486-1491
4. Mahale P, Kontoyiannis DP, Chemaly RF, Jiang Y, Hwang JP, Davila M, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol 2012; 57(6): 1177-1185
5. Locasciulli A, Bruno B, Alessandrino EP, Meloni G, Arcese W, Bandini G, et al. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant 2003; 31: 295-300
6. Strasser SI, Myerson D, Spurgeon CL, Sullivan KM, Storer B, Schoch HG, et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999; 29: 1893-1899
7. Ramos CA, Saliba RM, De Padua L, Khorshid O, Shpall EJ, Giralt S, et al. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 2009; 94: 249-257
8. Ozdogan O, Ratip S, Ahdab YA, Dane F, Ahdab HA, Imeryuz N, et al. Causes and risk factors for liver injury following bone marrow transplantation. J Clin Gastroenterol 2003; 36: 421-426
9. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002; 36: S114-S120
10. Bjorkstrand B. European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma. Semin Hematol 2001; 38: 219-225
11. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883
12. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184-4190
13. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant 2013; 19: 410-417
14. Khouri IF, Saliba RM, Hosing C, Okoroji G-J, Acholonu S, Anderlini P, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 2240-2247
15. Sperotto A, Silvestri F, Fanin R, Damiani D, Geromin A, Cerno M, et al. Feasibility of autologous stem cell transplantation in chronic carriers of hepatitis B and hepatitis C virus. Leuk Lymphoma 2000; 36: 323-330